Stakeholders request elaboration, consistency in FDA’s non-interventional RWE studies guidance
Reacting to new regulatory draft guidance on observational studies, stakeholders asked the US Food and Drug Administration (FDA) to flesh out its advice with examples and to ensure consistency with...